pennystockhaven
  • Facebook
  • Google
  • Pinterest
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » Anthera Pharmaceuticals (ANTH): Waiting at Bottoms

Anthera Pharmaceuticals (ANTH): Waiting at Bottoms

Posted on June 28, 2012 by PennyStockHaven in Commentary - 1 Comment
NASDAQ penny markets ANTH logo

Anthera Pharmaceuticals (ANTH) shares plunged around 70% after company’s report of the mixed results for its Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

Paul F. Truex, Anthera’s President and Chief Executive Officer, commented:

[quote style=”1″]The extensive data in the target severe population from our Phase 2 clinical program supports the initiation of a much smaller yet differentiated Phase 3 registration plan with the selected dose of blisibimod in patients with severe systemic lupus erythematosus. We have prospectively demonstrated for the first time the possibility for a subcutaneously administered BAFF inhibitor to be used in the treatment of a severe lupus population. The subgroup of severe patients from our Phase 2 study clearly identifies those patients most in need of therapy and most likely to benefit from our potent BAFF inhibitor blisibimod. Feedback from the EMA Scientific Advice process combined with an End of Phase 2 meeting in the third quarter will form the basis of our final phase 3 study designs.[/quote]

Market was definitely overreacted on this news; Anthera has confirmation from the European Medicines Agency (EMA) for the acceptability of the Company’s proposed Phase 3 design for the treatment of severe systemic lupus erythematosus patients as a basis for a marketing authorization application (MAA). The EMA feedback confirms that Anthera’s development program, including the heightened SRI-5 endpoint, is acceptable and that positive results from Phase 3 clinical studies in a severe lupus population would support approval of the product.

As of 11:45 a.m. EST ANTH stock traded one third of its floating shares and gave a nice opportunity to join it for the price below its cash/value for the swing trade.

NASDAQ penny markets ANTH logoAnthera Pharmaceuticals‚ Inc.
25801 Industrial Blvd, Suite B
Hayward‚ CA 94545
Tel: (510) 856–5600
Fax: (510) 856–5597
http://www.anthera.com/

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.

ANTH, Anthera Pharmaceuticals, Nasdaq penny markets

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018
  • Light Engine Design Corp (TLED): 50% gain into your pocket

    November 7, 2017
  • This Oil Company Is Poised For A Huge Run

    October 24, 2017
  • Curis, Inc. (CRIS) – Alert is still in Effect

    October 11, 2017
  • Curis, Inc. (CRIS) – Volume Alert (Technical Play)

    October 4, 2017
  • Trading idea with Ocean Power Technologies (Nasdaq: OPTT)

    April 26, 2017
  • Trading idea with ParkerVision, Inc. (NASDAQ: PRKR)

    April 12, 2017
  • Trading Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR)

    April 3, 2017
  • Gevo, Inc. (GEVO): Hit the Bottom

    March 12, 2017
    Micro & Small Cap Stocks

    * required

    *



    *



     
    Remember, if you’re not fully satisfied with our service, you can always opt-out of receiving our newsletter. We don’t spam and we’ll never sell your email to anyone else. We respect our subscribers’ privacy.

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Stocks

    • Financial Network
    • Free Investment Newsletter
    • Penny Stocks
    • Public Relations and Subscription Services
    eBay sniper

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2018 PennyStockHaven.com. All Rights Reserved